risperidone has been researched along with Bone Loss, Osteoclastic in 6 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aims of this study were to investigate bone mass, body composition and light microscopic pathology examinations of femur in an animal model of schizophrenia (pharmacologically induced by postnatally administered phencyclidine-PCP) and to further examine the effects of chronic treatment with risperidone on these parameters in rats." | 7.79 | Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia. ( Doknic, M; Jasovic-Gasic, M; Maric, N; Pekic, S; Petronijevic, M; Petronijevic, N; Popovic, V; Radonjic, N; Sopta, J, 2013) |
| "Risperidone was added to culture medium in clinically relevant doses of 0, 2." | 5.38 | Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. ( Baron, R; Bornstein, S; de Paula, FJ; Dick-de-Paula, I; Houseknecht, KL; Lotinun, S; Maloney, AE; Motyl, KJ; Rosen, CJ, 2012) |
| " The objective of this study was to determine the prevalence of low BMD in patients with schizophrenia treated with conventional antipsychotics or risperidone and to evaluate any potential relationship with treatment." | 5.17 | Bone loss associated with hyperprolactinemia in patients with schizophrenia. ( Jacob, J; Kinon, BJ; Liu-Seifert, H; Stauffer, VL, 2013) |
| "The aims of this study were to investigate bone mass, body composition and light microscopic pathology examinations of femur in an animal model of schizophrenia (pharmacologically induced by postnatally administered phencyclidine-PCP) and to further examine the effects of chronic treatment with risperidone on these parameters in rats." | 3.79 | Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia. ( Doknic, M; Jasovic-Gasic, M; Maric, N; Pekic, S; Petronijevic, M; Petronijevic, N; Popovic, V; Radonjic, N; Sopta, J, 2013) |
| "Risperidone was added to culture medium in clinically relevant doses of 0, 2." | 1.38 | Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. ( Baron, R; Bornstein, S; de Paula, FJ; Dick-de-Paula, I; Houseknecht, KL; Lotinun, S; Maloney, AE; Motyl, KJ; Rosen, CJ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Amini, A | 1 |
| Namvarpour, Z | 1 |
| Namvarpour, M | 1 |
| Raoofi, A | 1 |
| Motyl, KJ | 2 |
| Beauchemin, M | 1 |
| Barlow, D | 1 |
| Le, PT | 1 |
| Nagano, K | 1 |
| Treyball, A | 1 |
| Contractor, A | 1 |
| Baron, R | 2 |
| Rosen, CJ | 2 |
| Houseknecht, KL | 2 |
| Petronijevic, N | 1 |
| Sopta, J | 1 |
| Doknic, M | 1 |
| Radonjic, N | 1 |
| Petronijevic, M | 1 |
| Pekic, S | 1 |
| Maric, N | 1 |
| Jasovic-Gasic, M | 1 |
| Popovic, V | 1 |
| Lozano, R | 1 |
| Marin, R | 1 |
| Santacruz, MJ | 1 |
| Dick-de-Paula, I | 1 |
| Maloney, AE | 1 |
| Lotinun, S | 1 |
| Bornstein, S | 1 |
| de Paula, FJ | 1 |
| Kinon, BJ | 1 |
| Liu-Seifert, H | 1 |
| Stauffer, VL | 1 |
| Jacob, J | 1 |
1 trial available for risperidone and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Bone loss associated with hyperprolactinemia in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Bone Density; Bone Resorption; Cross-Sectional Studies; Estradiol; Fema | 2013 |
5 other studies available for risperidone and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Risperidone accelerates bone loss in rats with autistic-like deficits induced by maternal lipopolysaccharides exposure.
Topics: Animals; Animals, Newborn; Autistic Disorder; Behavior, Animal; Biomechanical Phenomena; Bone Resorp | 2020 |
A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice.
Topics: Animals; Antipsychotic Agents; Bone Resorption; Dopamine; Female; Mice; Mice, Inbred C57BL; Ovariect | 2017 |
Chronic risperidone exposure does not show any evidence of bone mass deterioration in animal model of schizophrenia.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Bone Density; Bone Resorption; Female; Male; Pregna | 2013 |
Pathological bone mineral density in patients on long-term risperidone.
Topics: Antipsychotic Agents; Bone Resorption; Female; Humans; Hyperprolactinemia; Male; Risperidone; Schizo | 2014 |
Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.
Topics: Adiposity; Administration, Oral; Animals; Antipsychotic Agents; Bone Density; Bone Resorption; Cell | 2012 |